Krystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Update

Krystal Biotech, Inc. (NASDAQ:KRYS) was the recipient of a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 3,370,000 shares, a drop of 8.9% from the December 31st total of 3,700,000 shares. Based on an average trading volume of 247,300 shares, the short-interest ratio is presently 13.6 days.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors have recently bought and sold shares of KRYS. Segall Bryant & Hamill LLC increased its holdings in Krystal Biotech by 352.4% during the third quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock valued at $28,605,000 after buying an additional 122,407 shares during the period. State Street Corp increased its holdings in Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after buying an additional 119,936 shares during the period. Franklin Resources Inc. increased its holdings in Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after buying an additional 62,178 shares during the period. Braidwell LP increased its holdings in Krystal Biotech by 57.4% during the third quarter. Braidwell LP now owns 168,691 shares of the company’s stock valued at $30,707,000 after buying an additional 61,512 shares during the period. Finally, TimesSquare Capital Management LLC increased its holdings in Krystal Biotech by 39.1% during the fourth quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company’s stock valued at $24,888,000 after buying an additional 44,646 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS opened at $159.74 on Monday. The firm has a market cap of $4.59 billion, a PE ratio of 90.25 and a beta of 0.84. The firm’s 50 day simple moving average is $165.65 and its 200-day simple moving average is $179.28. Krystal Biotech has a one year low of $107.50 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company’s quarterly revenue was up 879.9% compared to the same quarter last year. During the same period last year, the company posted ($0.67) earnings per share. Equities research analysts predict that Krystal Biotech will post 3.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Citigroup increased their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Chardan Capital reissued a “buy” rating and issued a $212.00 price objective on shares of Krystal Biotech in a research report on Wednesday, December 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Wednesday, December 18th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $206.67.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).